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Abstract 
 Breast cancer is one of the most prevalent forms of cancer among American women.  Vitamin D 
has been shown to reduce the risk of developing breast cancer, in part by preventing the formation of new 
blood vessels (termed angiogenesis) within tumors.  Vascular Endothelial Growth Factor (VEGF), a 
potent angiogenic factor, has been shown to be regulated by the active form of vitamin D, 1,25-
dihydroxyvitamin D (1,25(OH)2D).  It has been proposed that 1,25(OH)2D does not directly decrease the 
expression of VEGF, but rather acts indirectly through Hypoxia Inducible Factor-1α (HIF-1α), a direct 
transcriptional regulator of VEGF.  1,25(OH)2D may impact HIF-1α in one of two ways: gene 
transcription or stability of the protein, which is degraded through the actions of Prolyl Hydroxylase 
(PHD).  The purpose of this study was to determine the impact of 1,25(OH)2D on VEGF, HIF-1α, and 
PHD mRNA expression in MCF10A breast epithelial cells which are untransformed (LXSN) or which 
contain the ErbB2 oncogene.  ErbB2 is an oncogene that is commonly overexpressed and associated with 
an increased aggressiveness in breast cancer.  The MCF10A are a model of multistage carcinogenesis, 
models that are important to use when studying cancer prevention.  The hypothesis of this study is that 
1,25(OH)2D decreases the gene expression of VEGF and HIF-1α, and increases the gene expression of 
PHD in untransformed breast epithelial cells and breast epithelial cells transfected with ErbB2.  
Treatment of LXSN cells with increasing concentrations of 1,25(OH)2D (1 nM, 10 nM, and 100 nM) for 
24 hours resulted in increasing concentrations of VEGF mRNA and decreasing concentration of PHD 
mRNA levels compared to the vehicle control.  However, these differences were not significant (p>0.05) 
except at a high dose of 1,25(OH)2D (100 nM).  Increasing doses of 1,25(OH)2D did not significantly 
alter HIF-1α mRNA abundance (p>0.05) compared to the vehicle control.  Treatment of the ErbB2-
containing cells with the same increasing concentrations of 1,25(OH)2D showed no significant difference 
in the concentration of VEGF or HIF-1α mRNA (p>0.05) compared to the vehicle control.  The PHD 
mRNA expression decreased with increasing concentrations of 1,25(OH)2D, however this was only 
significant (p>0.05) at the high dose of 1,25(OH)2D (100 nM).  These results suggest that in 
untransformed MCF10A breast epithelial cells, 1,25(OH)2D increases the expression of VEGF mRNA at 
high doses, but not through an increased expression of HIF-1α mRNA.  In the MCF10A breast epithelial 






The purpose of this study was to determine the impact of 1,25(OH)2D on VEGF, HIF-1α, and 
PHD mRNA expression in untransformed MCF10A (LXSN) and oncogene (ErbB2) transfected MCF10A 
breast epithelial cells 
Literature & Rationale 
 Breast cancer is a form of cancer that is quite prevalent among American women.  The CDC 
reports that 186,467 women were diagnosed with breast cancer and 41,116 died from the disease in 
2005(16).  Breast cancer, like all forms of cancer, progresses through a series of steps that is termed 
multi-stage carcinogenesis (15).  Tumor development, or carcinogenesis, can be divided into 4 steps: 
tumor initiation, tumor promotion, malignant conversion, and tumor progression (13).  Tumor initiation is 
the result of the accumulation of irreversible genetic damage and is commonly the result of the activation 
of an oncogene.  An oncogene is a normally functioning gene in a cell that has been altered by mutation 
and acts to contribute to the growth of a tumor (4).  The next step in carcinogenesis is an accumulation of 
initiated cells and is termed tumor promotion.  Once there are a large number of initiated cells, they 
become susceptible to a malignant conversion.  This means that the initiated cells are altered to express a 
malignant phenotype, which usually causes the uncontrolled growth that is the hallmark characteristic of 
cancer cells.  The dominant step of carcinogenesis is tumor progression.  This is the step where the cell 
displays uncontrollable growth and the development of tumors.  Metastasis is also observed in this stage 
of cancer development. Metastasis is the process of the spreading of cancer from its initial site to other 
areas of the body (3).  Breast cancer is particularly fatal because of the increased likelihood of metastasis 
(9).  One gene that is an important regulator of metastatic potential and is responsible for the rapid growth 
found in the mammary epithelium tissues that is associated with the presence of this form of cancer is the 
ErbB2 oncogene (14,9).  An over expression of this oncogene is found in approximately 30% of breast 
cancer patients (9). 
 The rapid, uncontrollable growth of tumor cells requires in part, an increase in angiogenesis.  
Angiogenesis is the process of developing new blood vessels and is a major determinant in the growth of 
a tumor (12).  In order for tumor cells to grow and thrive, they must have a ready supply of oxygen and 
nutrients, which are supplied by the bloodstream.  The development of new blood vessels to tumor cells is 
critical for the growth of the tumor.  The process of angiogenesis has four stages: (1) degrading the 
basement membrane of existing vasculature, (2) proliferation and migration of endothelial cells, (4) 
attachment of preexisting endothelial cells to new channels, and (10) formation of new basement 
membrane and maturation of the new vasculature (12). 
 In addition to the other effects of ErbB2, the protein product of this oncogene is linked to an 
increased production of Vascular Endothelial Growth Factor (VEGF), a potent stimulator of angiogenesis 
(10).  The action of VEGF is primarily targeted towards the endothelial cell of the vasculature.  VEGF 
acts by binding to a receptor (VEGFR2) and activating a signaling cascade.  This cascade then acts to 
increase the permeability, proliferation, and migration of vascular endothelial cells (6).  Since the 
proliferation and migration of vascular endothelial cells are major events in angiogenesis, a compound 
with the ability to inhibit the production of VEGF may hinder the rapid growth of tumors and prevent the 
development of metastatic cancers.   
 Recently, the link between vitamin D and a decreased risk of cancer has received much attention 
(1).  Vitamin D is available in two main forms: in the diet or from a biological conversion that occurs in 
the skin.  Dietary sources of vitamin D include natural and fortified foods.  The most typical source of 
natural vitamin D is the fatty fish, such as salmon.  Some of the fortified sources of vitamin D include: 
milk, orange juice and some cereals (7).  The vitamin D that is produced in reaction to the absorption of 
sunlight represents the major source of vitamin D in most people.  When sunlight is absorbed by the 7-
dehydrocholesterol in an individual’s skin, it is converted to previtamin D3.  Previtamin D3 is quickly 
converted into a biologically significant isomer, vitamin D3.  Vitamin D3 is then released into the 
bloodstream where it binds to the vitamin D-binding protein (7). 
Once the vitaminD3 that is produced in the skin and the vitamin D that is consumed in the diet are 
present in the bloodstream they are taken up by the liver where they are metabolized to 25-
hydroxyvitamin D [25OHD].  The vitamin D metabolite 25OHD is the circulating form of vitamin D that 
is used to assess an individual’s vitamin D status.  However, this is not the biologically active form of 
vitamin D and another hydroxylation is required to produce the biologically active form 1,25-
dihydroxyvitaminD [1,25(OH)2D] (10).  25(OH)D was traditionally thought to be converted to 
1,25(OH)2D via the kidneys and functioned to regulate serum calcium levels, blood pressure, and insulin 
secretion (7).  However, it was discovered that extrarenal tissues, such as colon, prostrate, breast, and 
immune cells, also express the enzyme 25-hydroxyvitamin D-1α-hydroxylase (1-OHase) which is 
necessary in the conversion of 25(OH)D to 1,25(OH)2D.  1, 25(OH)2D which is produced in these 
extrarenal cells may act to inhibit cell proliferation and cell differentiation and act to induce apoptosis (5).  
It is this ability of 1,25(OH)2D in specific tissues to arrest cell growth and differentiation that is drawing 





There have been several studies performed testing the link between vitamin D and cancer.  In 
1941, epidemiological evidence was used to support an observation that individuals living in northern 
states in the United States were more likely to die of cancer than individuals living in the southern states 
(5).  This led others to consider the link between sunlight exposure, vitamin D status, and cancer risk.  
John, et al., analyzed data from The National Health and Nutrition Examination Survey (NHANES) I 
Epidemiologic Follow-up Study to look at the potential protective role of vitamin D in breast cancer risk 
(8).  They looked at the relationship of sunlight exposure and dietary intake of vitamin D to the 
development of breast cancer.  They found that women who lived in areas with adequate sunlight 
exposure and dietary intake of vitamin D were associated with a 25-65% reduction in breast cancer risk.  
It can be inferred from this data that adequate intake of vitamin D and a corresponding adequate vitamin 
D status provides breast cells with adequate substrate [25OHD] for conversion into the active form 
1,25(OH)2D, which in turn may act to inhibit tumor progression. 
Another study that was conducted to study the link between vitamin D status and tumor 
progression was performed by Tangpricha et al (8).  Tangpricha et al. studied the progression of a cancer 
cell line in mice that were vitamin D deficient or vitamin D sufficient.  They placed the cancer cells in the 
two mouse treatment groups and observed the growth of the tumor.  The mice that were vitamin D 
deficient had tumors that grew much more rapidly than the tumors in the vitamin D sufficient mice.  This 
observation suggests that vitamin D status is an important factor in the reduction of tumor growth and 
slowing cancer progression. 
In 2002, one study looked at the local production of 1,25(OH)2D and its role in inhibiting cancer 
growth (5).  They studied a prostate cancer cell line which either had 1-OHase or lacked 1-OHase 
activity.  It was found that the cells without 1-OHase were not able to use 25OHD but if they were treated 
with 1,25(OH)2D there was a marked decrease in cellular growth.  The cells that had active 1-OHase 
present also displayed a marked decrease in cellular growth.  This data also supports the theory that 
increased concentrations of 1,25(OH)2D in cancer cells is related to an inhibition of cellular growth. 
The exact mechanism of the role of vitamin D in the inhibition of cancer progression is not 
known.  However, a main role for vitamin D in cancer prevention appears to be the inhibition of 
angiogenesis (1).  Since VEGF is such a potent stimulator of angiogenesis, the link between the 
regulation of VEGF by 1,25(OH)2D and the progression of cancer is vital.  It is proposed that the action 
of the active vitamin D metabolite 1,25(OH)2D acts to decrease the expression of VEGF (1) in two ways: 
by decreasing the expression of HIF-1α mRNA or increasing the expression of Prolyl Hydroxylase (PHD) 
mRNA(Figure 1). 
 Figure 1 - Impact of increased concentrations of 1,25(OH)2D in cell models 
 
The active vitamin D compound, 1,25(OH)2D has been shown to decrease the concentration of 
Hypoxia Induced Factor1α (HIF-1α) mRNA.  This was shown by Ben-Shoshan et al, who demonstrated 
that treating prostate and colon cancer cells with increasing concentrations of 1,25(OH)2D reduced the 
levels of HIF-1α protein produced in a dose-dependent manner.  They also demonstrated in this study that 
this regulation of HIF-1α occurs during translation, decreasing the concentration of HIF-1α mRNA.  
While HIF-1α does not directly influence the process of angiogenesis, it has a role in activating 
angiogenic stimulators such as VEGF.  HIF-1α heterodimerizes with HIF-1β to form the HIF-1-
transcription factor (10).  This compound stimulates angiogenesis by binding to the promoter region of 
the VEGF gene and up-regulating VEGF mRNA expression (10).  This increase in VEGF mRNA 
expression leads to an increase in VEGF protein and a corresponding increase in angiogenesis. 
The other action of 1,25(OH)2D may be to increase the expression of PHD mRNA.  Increasing 
the expression of PHD mRNA leads to a corresponding increase in concentration of the PHD protein, 
which results in an increased degradation of the HIF-1α protein (2).  PHD contributes to the regulation of 
HIF-1α by binding to HIF-1α under normoxia conditions.  The resulting complex is targeted for 
degradation via a complex ubiquitin-proteasome pathway (8).  Although there is evidence that 
1,25(OH)2D both up and down-regulates the VEGF protein, dependent on the status of the cell(1), the 
mechanism by which 1,25(OH)2D mediates these changes has not been explored.  This study sought to try 





Study Design & Methods 
Cell Type 
 The MCF10A human epithelial breast cells were used in this experiment.  The MCF10A cells are 
derived from normal, untransformed tissues and maintained in Mammary Epithelial Growth Medium 
(MEGM).  The two cell models used include: MCF10A which expresses the ErbB2 oncogene and the 
untransformed MCF10A cell containing LXSN, the empty plasmid for the ErbB2 oncogene. 
Cell Treatments 
 The LXSN and the ErbB2 cell models were plated in 6-well-plates and treated with varying 
concentrations of 1,25(OH)2D.  The four experimental groups included: an ethanol vehicle, 1 nM 
1,25(OH)2D, 10 nM 1,25(OH)2D, and 100 nM 1,25(OH)2D.  The cells were harvested 24 hours following 
the treatment. 
Methods 
After harvest, total RNA was extracted and quantified.  Extraction of the RNA allowed the 
expression of HIF-1α, VEGF, and PHD mRNA to be assessed with real time polymerase chain reaction 
(PCR).  Primers for HIF-1α, VEGF, and PHD have been designed and optimized for the MCF10A cell 
line.   
 Human VEGF primer:  CAAGATCCGCAGACGTGTAA 
     TCACATCTGCAAGTACGTTCG 
 Human HIF-1 primer:  TGCTGAAGACACAGAAGCAAA 
     AAAGCGCAAGTCCTCAAAGC 
 Human GAPDH primer:  TCACCATCTTCCAGGAGCG 
     CTGCTTCACCACCTTCTTGA 
 Prolyl Hydroxylase primer: CTTTGACCGGTTGCTCATTT 
     TAGGCGGCTGTGATACAGGT 
 
The controls included no temperate controls and no RT, to ensure the lack of genomic DNA 
contamination.  The SYBR green system was used for visualization.  The normalization gene was 18S 
and data is expressed as ΔΔ Ct method for determination of fold change over control samples.  Standards 
were composed of aliquots of PCR products in 10-fold serial dilutions ranging from 109 to 101 molecules.  
Standards were amplified in triplicate and used to calculate a regression of threshold cycle on the 
molecule copy number to determine a log value of starting abundance for each cDNA aliquot, amplified 
in duplicate, based on individual threshold cycle.  The abundance of mRNA was analyzed, quantified, and 
statistically evaluated. 
Statistical Analysis  
 The statistical significance was assessed by an analysis of variance (ANOVA).  A statistical 




Impact of 1,25(OH)2D on VEGF mRNA expression in Untransformed Breast Epithelial Cells 
 In the untransformed breast epithelial cells, the LXSN cell line, increasing concentrations (1 nM, 
10 nM, 100 nM) of 1,25(OH)2D did not significantly impact the expression of VEGF mRNA at a 
physiological of 10 nM(Figure 2).  However, at the higher concentration (100 nM) an increase was 
observed, although this increase was not significant (p>0.05).  There was also a decrease observed at the 
low concentration (1 nM) which had a p-value with a trend toward significant (0.05 < p < 0.10). 
 
Impact of 1,25(OH)2D on HIF-1α mRNA expression in Untransformed Breast Epithelial Cells 
 In the untransformed breast epithelial cells, the LXSN cell line, increasing concentrations (1 nM, 
10 nM, 100 nM) of 1,25(OH)2D did not significantly impact the expression of HIF-1α  mRNA within a 
physiological range of 10 nM or less (Figure 3).  However, at the higher concentration (100 nM) an 
increase was observed, but was not significant (p>0.05).  There was a significant difference (p > 0.05) 
between the 1 nM and 100 nM treatments, but not between either of these treatments and the vehicle. 
 
Impact of 1,25(OH)2D on PHD mRNA expression in Untransformed Breast Epithelial Cells 
 In the untransformed breast epithelial cells, the LXSN cell line, increasing concentrations (1 nM, 
10 nM, 100 nM) of 1,25(OH)2D did not significantly impact the expression of PHD mRNA at a 
physiological level of 10 nM (Figure 4).  However, at high concentrations (100 nM) there was a decrease 
in the amount of PHD mRNA, although this decrease was not significant (p > 0.05).  There was a 
significant difference (p > 0.05) between the 1 nM and 100 nM treatments, but not between either of these 



































Figure 2 - The Regulation of VEGF mRNA Expression by 1,25(OH)2D.  Untransformed (LXSN) cells were treated with 
vehicle or increasing concentrations of 1,25(OH)2D, and following harvest the expression of VEGF mRNA assessed by 




































Figure 3 – The Regulation of HIF-1α mRNA Expression by 1,25(OH)2D.  Untransformed (LXSN) cells were treated with 
vehicle or increasing concentrations of 1,25(OH)2D, and following harvest the expression of VEGF mRNA assessed by 
































Figure 4 – The Regulation of PHD mRNA Expression by 1,25(OH)2D.  Untransformed (LXSN) cells were treated with 
vehicle or increasing concentrations of 1,25(OH)2D, and following harvest the expression of VEGF mRNA assessed by 
PCR.  Bars with different letters are significantly different (p-value < 0.05) as assessed by ANOVA. 
 
 
Impact of 1,25(OH)2D on VEGF mRNA expression in Breast Epithelial Cells Transfected with ErbB2 
 In the breast epithelial cells transfected with the ErbB2 oncogene, increasing concentrations       
(1 nM, 10 nM, 100 nM) of 1,25(OH)2D did not significantly impact the expression of VEGF mRNA 
(Figure 5).   
 
Impact of 1,25(OH)2D on HIF-1α mRNA expression in Breast Epithelial Cells Transfected with ErbB2 
 In the breast epithelial cells transfected with the ErbB2 oncogene, increasing concentrations        
(1 nM, 10 nM, 100 nM) of 1,25(OH)2D did not significantly impact the expression of HIF-1α  mRNA 
(Figure 6). 
 
Impact of 1,25(OH)2D on PHD mRNA expression in Breast Epithelial Cells Transfected with ErbB2 
 In the breast epithelial cells transfected with the ErbB2 oncogene, increasing concentrations (1 
nM, 10 nM, 100 nM) of 1,25(OH)2D did not significantly impact the expression of PHD mRNA at 
physiological level of 10 nM (Figure 7).  However, at high concentrations (100 nM), 1,25(OH)2D  acted 
































Figure 5 – The Regulation of VEGF mRNA Expression by 1,25(OH)2D.  Epithelial cells transfected with the ErbB2 
oncogene were treated with vehicle or increasing concentrations of 1,25(OH)2D, and following harvest the expression of 



































Figure 6 – The Regulation of HIF-1α mRNA Expression by 1,25(OH)2D.  Epithelial cells transfected with the ErbB2 
oncogene were treated with vehicle or increasing concentrations of 1,25(OH)2D, and following harvest the expression of 

































Figure 7 - The Regulation of PHD mRNA Expression by 1,25(OH)2D.  Epithelial cells transfected with the ErbB2 
oncogene were treated with vehicle or increasing concentrations of 1,25(OH)2D, and following harvest the expression of 





 In this study we treated two cell lines, untransformed breast epithelial cells and breast epithelial 
cells transfected with the ErbB2 oncogene, with varying concentrations (1 nM, 10 nM, & 100 nM) of 
1,25(OH)2D for 24 hours.  We then isolated and quantified the RNA from these cells and performed a 
PCR test to determine the amount of mRNA that was present in the cells.  We looked at the amount of 
VEGF, HIF-1α, and PHD present in these cells. 
 There were two main questions that were considered with this study.  First, was to determine 
what the effect of 1,25(OH)2D was on the gene expression of VEGF, HIF-1α, and PHD in untransformed 
breast epithelial.  Upon statistical analysis of the data, we observed trends.  With respect to VEGF, it 
appeared that as the concentration of 1,25(OH)2D increased, the concentration of VEGF mRNA increased 
in the untransformed cells, although the results were not statistically significant (Figure2).  The 
expression of HIF-1α mRNA did change with increasing concentrations of 1,25(OH)2D , except at a high 
concentration of 100 nM, although this increase was not significant (Figure 3).  The PHD mRNA 
decreased, though not significantly, with increasing concentrations of 1,25(OH)2D (Figure 4).  We 
expected that the VEGF and HIF-1α mRNA would increase together since HIF-1α is a regulator of 
VEGF.  However, this might be explained by alterations in protein level.  In our laboratory, other students 
determined the effect of treatment of untransformed cells and cells transfected with the ErbB2 oncogene 
with the same varying concentrations of 1,25(OH)2D (1 nM, 10 nM, 100 nM) on protein expression of 
HIF-1α.  They showed that in the untransformed cells, increasing concentrations of 1,25(OH)2D 
corresponded with an increasing expression of HIF-1α protein.  This suggests that VEGF might be 
regulated by HIF-1α at a protein level rather than at a transcriptional level.  This hypothesis is supported 
by the decrease in PHD mRNA expression.  With less PHD being expressed, there might be less PHD 
protein to degrade the HIF-1α protein and more available HIF-1α protein available to alter VEGF 
transcription. 
 The other main question that was considered in this study was the effect of the ErbB2 oncogene 
on the 1,25(OH)2D-induced gene expression of VEGF.  The VEGF mRNA expression in the ErbB2 cells 
appeared to decrease with increasing concentrations of 1,25(OH)2D (Figure 5).  However, this trend was 
not significant (p > 0.05).  There did not appear to be a significant difference in the gene expression of 
HIF-1α in the ErbB2 transfected cells (Figure 6).  The expression of PHD was not significantly different 
except at high concentrations (100 nM) of 1,25(OH)2D (Figure 7).  The protein expression of HIF-1α 
determined in our laboratory indicated that protein expression of HIF-1α in ErbB2 cells was not 
significantly different from the vehicle.  While the trends in VEGF expression are not significant, they are 
similar to the decreases in VEGF mRNA expression with treatment of 1,25(OH)2D that are found in the 
literature (1).  It may be that with a larger sample size and subsequent reduction in error, a statistically 
significant result would be achieved. 
Conclusion 
 In untransformed MCF10A breast epithelial cells, 1,25(OH)2D increases the expression of VEGF 
mRNA but not through an increased expression of HIF-1α.  We also observed that in MCF10A breast 
epithelial cells transfected with the ErbB2 oncogene 1,25(OH)2D did not significantly impact the 
expression of VEGF or HIF-1 α expression. 
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